Human research through 2026

Evidence Summary

A balanced, tightly referenced synthesis of human clinical and observational research on ibogaine and noribogaine: study designs, endpoints, reported outcomes, and the limits that shape interpretation.

For people researching In F in Ig a in E, this page keeps the emphasis on what has been studied rather than on treatment claims. It distinguishes randomized and non-randomized work, prospective and retrospective cohorts, case series, and safety reporting.

This is not dosing guidance or an endorsement of clinical use. Reported outcomes are not evidence that an intervention is safe, appropriate, or effective for an individual.

Close-up visual detail accompanying the ibogaine human research evidence summary

01 / Study explorer

Read the evidence by research question

These panels group the available human literature by population and outcome focus. The evidence base is uneven: studies differ in selection, setting, follow-up, outcome measurement, co-interventions, and completeness of adverse-event reporting.

Focus panel / OUD

Opioid-use disorder: the largest, still limited body of human work

Published OUD research includes observational treatment-setting reports, small prospective follow-up studies, retrospective surveys, and case series. Endpoints commonly include withdrawal severity, self-reported opioid use, retention, and follow-up abstinence or reduction measures. These endpoints are not standardized across reports.

Design: mostly non-randomized
Samples: generally small
Endpoints: varied
Bias risk: substantial

Several reports describe short-term changes after an ibogaine-associated intervention, but unblinded designs, self-selection, attrition, concurrent support, and inconsistent toxicology confirmation limit causal interpretation. Randomized comparative evidence remains sparse. The broader Infinigaine evidence and safety overview provides context for how this research fits with practical questions people may have.

Interpretation: reported post-treatment outcomes may reflect multiple influences. They should not be read as a basis for predicting an individual result.

02 / Conditions & outcomes

What the studies measure — and what they cannot settle

Ibogaine is commonly discussed in relation to substance use, while noribogaine is its active metabolite in human pharmacology research. The ibogaine overview in Wikipedia is useful for basic background, but the records below focus narrowly on the quality and limits of human evidence.

Research materials visual accompanying a comparison of ibogaine study designs and outcomes

PTSD and trauma-related symptoms

Human reports in this area are limited and often involve observational cohorts or naturalistic treatment settings, sometimes with military-veteran participants and mixed co-occurring conditions. Measures may include self-reported PTSD symptom scales assessed before and after an intervention.

Small samples, no control group, expectations, concurrent psychotherapy or supportive care, and incomplete follow-up are central bias risks. A change on a symptom scale is a reported study outcome, not a demonstration of comparative efficacy or durable clinical benefit.

Alcohol-use disorder

Alcohol-focused human evidence is comparatively sparse. Available material includes early clinical observations and broader substance-use cohorts in which alcohol use may be one of several reported outcomes. Sample sizes and outcome definitions vary too much for simple comparison.

Where alcohol-use outcomes are self-reported, recall bias and loss to follow-up matter. The National Institute on Alcohol Abuse and Alcoholism’s description of alcohol use disorder helps clarify why diagnostic criteria and validated outcome measures are important when reading these studies.

Other substances and mixed samples

Case series and naturalistic reports may include people reporting stimulant, alcohol, polysubstance, or other substance use. Their heterogeneity can be informative about what was observed in a setting, but it makes condition-specific conclusions especially uncertain.

Mixed samples can also obscure differences in baseline risk, concurrent medicines, withdrawal state, psychosocial support, and follow-up opportunity. This is why outcomes cannot reliably be transferred from one substance-use population to another.

Safety reports and adverse-event evidence

Safety literature includes case reports, case series, toxicology reports, regulatory discussions, and reviews. Serious cardiac events and deaths have been reported in some contexts. Attribution is complicated by co-exposures, pre-existing conditions, incomplete histories, and differences in monitoring.

Cardiac interpretation should not be separated from the evidence synthesis: review the dedicated cardiac safety profile for a focused account of arrhythmia-related concerns, QT effects, and why incomplete adverse-event ascertainment affects confidence.

03 / Regulatory status

Regulatory status & trials

Ibogaine’s legal and research status differs by jurisdiction. In the United States, ibogaine is listed as a Schedule I controlled substance; the DEA controlled substances schedule records its federal classification. Classification does not substitute for a full account of research quality or medical risk.

1967–1970
U.S. federal scheduling placed ibogaine within the controlled-substances framework; research access consequently requires formal regulatory pathways.
1990s–2000s
Human reports and early clinical research continued alongside case-based safety literature, with most evidence remaining non-randomized.
2023–2025
Federal interest in novel approaches to substance-use research remained visible across agencies. ARPA-H’s official program information describes its broader role in high-impact health research rather than establishing ibogaine efficacy.
Through 2026
Study registries and peer-reviewed publication remain the appropriate places to verify active protocols, sponsors, outcomes, and publication status. Absence of a result is not evidence of a negative or positive finding.

04 / Methods note

How this synthesis is framed

This summary is designed for readers who need an evidence-first map, not a treatment recommendation. It includes human clinical and observational material on ibogaine or noribogaine available through 2026, with attention to randomized and non-randomized trials, prospective and retrospective cohorts, case series, and major safety reports.

Priority is given to records that identify population, design, approximate sample size, endpoints, follow-up, and adverse-event reporting. Animal and laboratory work can inform mechanism questions but is not treated here as direct evidence of human outcomes. For questions about how evidence is selected and described across the site, see the resource’s approach to evidence and independence.

Evidence is strongest when comparison groups, predefined outcomes, complete follow-up, and transparent safety reporting reduce the room for alternative explanations.

Search framing draws on biomedical databases, trial registries, safety-focused literature, and official regulatory materials. A literature review cannot eliminate publication bias, inaccessible records, selective reporting, or the variability of unregulated settings. The research gaps and protocol guide examines those limitations in greater detail.

05 / Reading notes

Questions that change how evidence should be read

Study claims deserve a proportionate reading. The most important details are often the design and missing information, not only the headline outcome.

Does this evidence summary establish that ibogaine is effective?

No. The human literature includes small, non-randomized, observational, and retrospective reports with important limits. Outcomes should be read as observations from particular study settings, not as proof of efficacy.

Why are safety reports discussed alongside outcome studies?

Interpretation requires both outcome and risk information. Published reports have described serious cardiac events and deaths in some contexts, while uneven screening and reporting make direct comparisons difficult. The research gaps and protocol guide explains why standardized reporting matters for future studies.

Does this page provide dosing or treatment recommendations?

No. This is an independent information resource. It does not provide dosing guidance, endorse clinical use, or replace medical or legal advice. People researching mood-related questions may also encounter discussion at ibogaine treatment for depression, but condition-specific claims should be checked against the underlying human research and its limits.